Stephan Bernstein, CEO of GreenRoc, details the PFS results for the new graphite processing plant. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,118.00
Bid: 12,120.00
Ask: 12,124.00
Change: 68.00 (0.56%)
Spread: 4.00 (0.033%)
Open: 11,966.00
High: 12,162.00
Low: 11,966.00
Prev. Close: 12,050.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Thursday preview: US jobless claims, AstraZeneca in the spotlight

Wed, 10th Feb 2021 18:52

(Sharecast News) - The economic calendar on Thursday will be exceedingly light with a reading on weekly US unemployment claims the only event that might easily move markets.



Consensus is expecting but a slight drop in the number of initial jobless claims from 779,000 for the week before to 769,000.

A speech from European Central Bank vice-president, Luis De Guindos, will also be worth monitoring.

No major economic releases are scheduled in the UK.

Further afield, rate-setters in Manila are due to meet to decide on policy.



For AstraZeneca's fourth quarter, UBS analyst Michael Leuchten has penciled sales of $7.22bn, putting him slightly ahead of the consensus which is at $7.16bn.

Core operating profits on the other hand were pegged to come in at $1.94bn (consensus: $2.02bn) for earnings per share of $1.04 (consensus: $1.09).

"Top-line momentum remains key for investors," he said, adding that he expected investors to focus their questions on the outfit's business in China, which accounts for approximately a fifth of its sales.

The analyst also broke down his sales forecasts for AstraZeneca's key treatments: Tagrisso ($1.15bn), Lynparza ($483m), Imfinzi ($532m) and Calquence ($157m).

Going forwards, Leuchten expected AstraZeneca would guide towards single-digit topline growth - excluding vaccines - and for mid-to-high teens growth in earnings per share, with the latter not including gains from the spin-out of Viela.

Thursday 11 February

INTERIMS

MJ Gleeson

INTERIM EX-DIVIDEND DATE

Hargreaves Lansdown, Henderson Smaller Companies Inv Trust, PZ Cussons, The Mission Group

QUARTERLY EX-DIVIDEND DATE

BMO Commercial Property Trust Limited, Chenavari Toro Income Fund Limited NPV, Custodian Reit , ICG Enterprise Trust, The Renewables Infrastructure Group Limited

INTERNATIONAL ECONOMIC ANNOUNCEMENTS

Continuing Claims (US) (13:30)

Initial Jobless Claims (US) (13:30)

Q4

AstraZeneca

GMS

Coral Products, Tesco

FINALS

AstraZeneca, Coca-Cola European Partners (DI), Coca-Cola HBC AG (CDI), Relx plc, Yamana Gold Inc. NPV (CDI)

SPECIAL EX-DIVIDEND DATE

Anglo Asian Mining

EGMS

Glanbia, Law Debenture Corp.

AGMS

Euromoney Institutional Investor

UK ECONOMIC ANNOUNCEMENTS

RICS Housing Market Survey (00:01)

FINAL DIVIDEND PAYMENT DATE

Hargreave Hale AIM VCT , Sage Group, Unicorn AIM VCT

FINAL EX-DIVIDEND DATE

Aberforth Smaller Companies Trust, Avon Rubber, Blackrock Income And Growth Investment Trust, Northamber
More News
Today 15:54

Berenberg hikes target price on Astrazeneca

(Sharecast News) - Analysts at Berenberg hiked their target price on drugmaker Astrazeneca from 1,200.0p to 1,300.0p on Tuesday, citing the group was "instilling confidence in the revenues of tomorrow".

Read more
Today 09:51

LONDON BROKER RATINGS: AstraZeneca target raised; Antofagasta lowered

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and Friday:

Read more
6 May 2024 07:46

AstraZeneca completes collaboration and investment deal with Cellectis

(Alliance News) - AstraZeneca PLC on Monday said it has completed an equity investment in clinical-stage biotechnology company Cellectis, first announced in November.

Read more
3 May 2024 12:17

CORRECT: Angle shares up on assay development deal with AstraZeneca

(Correcting company name in headline)

Read more
3 May 2024 11:50

Angle shares up on assay development deal with AstraZenaca

(Alliance News) - Shares in Angle PLC jumped on Friday, after the company said it has been chosen to develop a prostate cancer assay using its Parsortix technology, opening the door for future clinical study-supporting contracts.

Read more
3 May 2024 07:50

LONDON BRIEFING: InterContinental Hotels makes first-quarter progress

(Alliance News) - London's FTSE 100 is called to open higher on Friday, on the expectation of a softer US jobs report, which could take some sting out of hawkish Federal Reserve interest rate expectations.

Read more
2 May 2024 10:04

AstraZeneca notes positive trial results for Calquence treatment

(Alliance News) - AstraZeneca PLC on Thursday said it observed positive high-level results in the Echo phase 3 trial of its Calquence treatment for previously untreated adult patients with mantle cell lymphoma.

Read more
2 May 2024 07:45

AstraZeneca reports positive results from blood cancer drug trial

(Sharecast News) - AstraZeneca has reported positive results from the use of its Calquence drug in a clinical trial to treat a rare type of blood cancer.

Read more
29 Apr 2024 22:52

J&J, Bristol Myers lose challenges to US drug price negotiation program

April 29 (Reuters) - A U.S. judge on Monday rejected a challenge by Bristol Myers Squibb and Johnson & Johnson to a law requiring them to negotiate the prices of their blockbuster blood clot prevention drugs with the U.S government's Medicare health insurance program or pay heavy penalties.

Read more
29 Apr 2024 10:02

LONDON BROKER RATINGS: Deutsche Bank likes Frasers; Barclays cuts JD

(Alliance News) - The following London-listed shares received analyst recommendations Monday morning and Friday:

Read more
29 Apr 2024 09:13

AstraZeneca makes progress with Truqap and Enhertu cancer treatments

(Alliance News) - AstraZeneca PLC on Monday said its Truqap drug has been recommended for approval in the EU to treat a form of breast cancer, while also noting trial results for its Enhertu offering.

Read more
29 Apr 2024 07:50

LONDON BRIEFING: Hipgnosis Songs Fund backs new Blackstone bid

(Alliance News) - London's FTSE 100 is called to open higher on Monday, with heady gains for US tech stocks on Friday brightening the mood in Europe and Asia at the start of the new week.

Read more
29 Apr 2024 07:24

AstraZeneca makes progress with two breast cancer treatments

(Sharecast News) - AstraZeneca issued favourable updates on two of its breast cancer treatments on Monday - 'Truqap', or capivasertib, and 'Enhertu', or trastuzumab deruxtecan - following encouraging results from respective phase three trials.

Read more
26 Apr 2024 09:33

LONDON BROKER RATINGS: Peel Hunt cuts ConvaTec to 'reduce'

(Alliance News) - The following London-listed shares received analyst recommendations Friday morning:

Read more
25 Apr 2024 16:57

LONDON MARKET CLOSE: FTSE 100 shakes off red-hot US inflation gauge

(Alliance News) - London's FTSE 100 outperformed on Thursday, enjoying a solid rise on largely well-received corporate earnings and a share price jump for miner Anglo American after it received a takeover bid from peer BHP.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.